

Amitkumar Mehta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7438007/publications.pdf>

Version: 2024-02-01

35
papers

580
citations

687363

13
h-index

642732

23
g-index

35
all docs

35
docs citations

35
times ranked

1074
citing authors

#	ARTICLE	IF	CITATIONS
1	Transcriptional determinants of cancer immunotherapy response and resistance. <i>Trends in Cancer</i> , 2022, 8, 404-415.	7.4	9
2	High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors. <i>Journal of Neuro-Oncology</i> , 2022, 158, 33-40.	2.9	0
3	Phase 2 study of piasclisib (INCB050465), a highly selective, next-generation PI3K $\hat{\nu}$ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). <i>Leukemia and Lymphoma</i> , 2021, 62, 368-376.	1.3	23
4	Co-Occurrence of Familial Hemophagocytic Lymphohistiocytosis Type 2 and Chronic Active Epstein-Barr Virus in Adulthood. <i>American Journal of the Medical Sciences</i> , 2021, 361, 388-393.	1.1	4
5	CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges. <i>Annals of Translational Medicine</i> , 2021, 9, 1036-1036.	1.7	3
6	Healthcare utilization and spending among older patients diagnosed with Non-Hodgkin lymphoma. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1225-1232.	1.0	1
7	Efficacy and Safety of Piasclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205). <i>Blood</i> , 2021, 138, 382-382.	1.4	8
8	TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data. <i>Blood</i> , 2021, 138, 2488-2488.	1.4	2
9	Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 18-27.	4.1	46
10	A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2020, 136, 2401-2409.	1.4	92
11	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262.	5.2	29
12	Phase 2 Study Evaluating the Efficacy and Safety of Piasclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205). <i>Blood</i> , 2020, 136, 43-44.	1.4	10
13	Phase 2 Study Evaluating the Efficacy and Safety of Piasclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205). <i>Blood</i> , 2020, 136, 22-23.	1.4	8
14	A review of chimeric antigen receptor T-cells in lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 551-561.	2.2	11
15	The impact of structural factors on diagnostic delay in diffuse large B-cell lymphoma. <i>Cancer Medicine</i> , 2019, 8, 1416-1422.	2.8	3
16	Phase 2 study of piasclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).. <i>Journal of Clinical Oncology</i> , 2019, 37, e19038-e19038.	1.6	3
17	Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor Therapy. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2018, 2, 74-77.	2.4	30
18	Improving shared decision-making in chronic lymphocytic leukemia through multidisciplinary education. <i>Translational Behavioral Medicine</i> , 2018, 8, 175-182.	2.4	10

#	ARTICLE	IF	CITATIONS
19	Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets. <i>European Urology Focus</i> , 2018, 4, 733-736.	3.1	18
20	Congestive heart failure in older adults diagnosed with follicular lymphoma: A population-based study. <i>Cancer</i> , 2018, 124, 4221-4230.	4.1	8
21	Treatment approaches of hard-to-treat non-Hodgkin lymphomas. <i>Expert Review of Hematology</i> , 2017, 10, 259-273.	2.2	9
22	Diagnostic, prognostic and therapeutic role of CD30 in lymphoma. <i>Expert Review of Hematology</i> , 2017, 10, 29-37.	2.2	43
23	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , 2017, 92, 161-170.	4.1	56
24	Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets. <i>Oncotarget</i> , 2017, 8, 21710-21718.	1.8	14
25	Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin. <i>Leukemia Research</i> , 2016, 44, 25-31.	0.8	42
26	Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy. <i>Expert Review of Hematology</i> , 2016, 9, 471-477.	2.2	18
27	Patient activation measures, distress levels, and causes of distress in chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2016, 34, 201-201.	1.6	3
28	Shared decision-making in chronic lymphocytic leukemia: Preferences and perceptions of patients, providers, and navigators.. <i>Journal of Clinical Oncology</i> , 2016, 34, 221-221.	1.6	0
29	Late Morbidity and Mortality Among 2-Year Survivors of Non-Hodgkin Lymphoma (NHL) Diagnosed in the Elderly - a Population-Based Study. <i>Blood</i> , 2016, 128, 539-539.	1.4	0
30	EZH2 Upregulation Is Associated with Unfavorable Prognosis in Diffuse Large B-Cell Lymphoma through Potential RUNX3 Downregulation. <i>Blood</i> , 2016, 128, 5301-5301.	1.4	0
31	High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes. <i>PLoS ONE</i> , 2015, 10, e0139267.	2.5	34
32	Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma. <i>Current Oncology Reports</i> , 2015, 17, 41.	4.0	31
33	How Do I Recommend Extended Adjuvant Hormonal Therapy?. <i>Current Treatment Options in Oncology</i> , 2014, 15, 55-62.	3.0	3
34	Disseminated fusariosis during acute myelogenous leukemia induction treatment. <i>Blood</i> , 2014, 123, 3379-3379.	1.4	1
35	Anti CD-30 Antibody-Drug Conjugate Brentuximab Vedotin (ADCETRISÂ®) May Be a Promising Treatment Option for Systemic Mastocytosis (SM).. <i>Blood</i> , 2012, 120, 2857-2857.	1.4	8